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OPEN
ORIGINAL ARTICLE
Anxiety and depression with neurogenesis defects in exchange
protein directly activated by cAMP 2-deﬁcient mice are
ameliorated by a selective serotonin reuptake inhibitor, Prozac
L Zhou1,10, SL Ma2,10, PKK Yeung1,3, YH Wong4,5, KWK Tsim5,6, KF So1,7,8,9, LCW Lam2 and SK Chung1,3,7
Intracellular cAMP and serotonin are important modulators of anxiety and depression. Fluoxetine, a selective serotonin reuptake
inhibitor (SSRI) also known as Prozac, is widely used against depression, potentially by activating cAMP response element-binding
protein (CREB) and increasing brain-derived neurotrophic factor (BDNF) through protein kinase A (PKA). However, the role of Epac1
and Epac2 (Rap guanine nucleotide exchange factors, RAPGEF3 and RAPGEF4, respectively) as potential downstream targets of
SSRI/cAMP in mood regulations is not yet clear. Here, we investigated the phenotypes of Epac1 (Epac1− /−) or Epac2 (Epac2− /−)
knockout mice by comparing them with their wild-type counterparts. Surprisingly, Epac2− /− mice exhibited a wide range of mood
disorders, including anxiety and depression with learning and memory deﬁcits in contextual and cued fear-conditioning tests
without affecting Epac1 expression or PKA activity. Interestingly, rs17746510, one of the three single-nucleotide polymorphisms
(SNPs) in RAPGEF4 associated with cognitive decline in Chinese Alzheimer’s disease (AD) patients, was signiﬁcantly correlated with
apathy and mood disturbance, whereas no signiﬁcant association was observed between RAPGEF3 SNPs and the risk of AD or
neuropsychiatric inventory scores. To further determine the detailed role of Epac2 in SSRI/serotonin/cAMP-involved mood
disorders, we treated Epac2− /− mice with a SSRI, Prozac. The alteration in open ﬁeld behavior and impaired hippocampal cell
proliferation in Epac2− /− mice were alleviated by Prozac. Taken together, Epac2 gene polymorphism is a putative risk factor for
mood disorders in AD patients in part by affecting the hippocampal neurogenesis.
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INTRODUCTION
Overlapping cerebral regions, circuits and cellular signaling
pathways underpin comorbid cognitive decline and emotional
disorders.1 Therefore, understanding the common molecular and
cellular mechanisms underlying the progression of cognitive
decline and concomitant affective traits, such as anxiety, apathy
and depression, is critical for developing potential therapies of
both cognitive impairment and mood disorders. Recently, it is
reported that anxiety is associated with the accumulation of
in vivo biomarkers t-tau and Aβ42 in the cerebrospinal ﬂuid of
patients with mild cognitive impairment.2 Correspondingly,
anxiety and neuronal alteration in the hippocampus are found
in a young Alzheimer’s disease (AD) mouse model without
amyloid deposition.3 The early involvement of the emotionality
factor may reﬂect the underlying AD pathology and provide new
strategies for an earlier diagnosis.
The functional signiﬁcance of adult hippocampal neurogenesis
has been demonstrated in learning and memory,4 emotional
behaviors5 and neurodegenerative disorders, such as AD.6
Efﬁcacy of selective serotonin reuptake inhibitors (SSRIs), such
as ﬂuoxetine, involved the upregulation of hippocampal
neurogenesis.7 Fluoxetine and rolipram (selective PDE4 inhibitor)
exert their antidepressant-like and neurogenic effects by increas-
ing the cAMP level, and subsequently activating cAMP response
element-binding protein (CREB).8,9 Thus far, the effects of
antidepressants on CREB are mostly analyzed with regard to the
cAMP-dependent protein kinase A (PKA) pathway and its target
brain-derived neurotrophic factor (BDNF).10 However, it is not clear
whether the PKA/CREB pathway directly targets the proliferating
progenitor cells or indirectly increases neurogenesis by promoting
survival of polysialylated-neural cell adhesion molecule-positive
immature neurons.11 Besides, Epac has been found to mediate
cAMP signaling independent of PKA; therefore, the mechanistic
role of the cAMP signaling pathway in cognitive and affective
functions has to be re-evaluated. The two isoforms of Epac, Epac1
and Epac2, directly bind to cAMP and activate the Ras-like small
GTPase Rap1/2.12 Epac1 is ubiquitously expressed, whereas Epac2
is relatively restricted in the brain and the adrenal glands.13 Recent
microarray data have shown that Epac2 is highly expressed in the
amygdala and the hippocampus of human brains, which are the
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regions responsible for emotional reaction and learning.14 Altered
expression and activation of Rap1 and Epac2 in the hippocampus
are shown in a post-mortem study on depressed suicide victims.15
The selective PKA inhibitor (Rp-8-Br-cAMP) increases cAMP levels
in the hippocampus of rats, and reduces their behavioral despairs
in the forced swimming test,16 suggesting that Epac may exert its
antidepressive effects through pathways downstream to the cAMP
signal. Supporting such notion, stimulation with the Epac analog
shows beneﬁcial effects on hippocampus-dependent memory
functions in mice.17,18 However, it is not clear which isoform of
Epac is predominantly contributive to the antidepressant effect
and improves cognitive function.
In the present study, Epac wild-type (WT), Epac1− /−, Epac2− /−
and Epac1;Epac2 double knockout (Epac1− /−;2− /−) mice were
used to investigate the roles of Epac in anxiety and depressive
disorders, as well as cognitive deﬁcits. Further, to study the impact
of Epac mutation in human disease, we examined several single-
nucleotide polymorphisms (SNPs) in RAPGEF3 and RAPGEF4 (gene
encoding Epac1 and Epac2, respectively) of Chinese AD patients,
and performed the Neuropsychiatric Inventory (NPI) scoring.
MATERIALS AND METHODS
Animals
All animal experiments were performed according to the guidelines set
forth by the Committee on the Use of Live Animals in Teaching and
Research at The University of Hong Kong. Mice were housed with a 12-h
light/dark cycle (L 0700 to 1900 hours) and ad libitum access to food and
water. Targeted deletion of Epac1 was achieved by homologous
recombination in a process described in detail previously.19 Epac2− /−
mice were kindly provided by Professor Susumu Seino’s group at Kobe
University Graduate School of Medicine.20 Epac1− /− and Epac2− /− mice
were backcrossed to the C57BL/6 for at least 10 generations. Epac1− /−;2− /−
mice were generated by cross-breeding with Epac1− /− and Epac2− /− mice.
C57BL/6 mice were used as WT control. Eight- to twelve-week male WT,
Epac1− /−, Epac2− /− and Epac1− /−;2− /− mice were used in all experiments,
unless otherwise stated.
Behavioral tests
Open ﬁeld test. Open ﬁeld test is a well-established behavioral assessment
to the locomotor activity and anxiety related behavior.21 The open ﬁeld
was a transparent (26 cm length× 26 cm width × 40 cm height) box with
equivalent mouse bedding. The 10 cm×10 cm square in the center of the
box was deﬁned as center arena. Four mice were detected in individual
boxes at the same time and cardboards were placed in between to avoid
disturbance. Mice were allowed to move freely in the open ﬁeld for 10min
or 1 h. Their movements were video tracked and analyzed by EthoVision
3.0 (Noldus, Wageningen, The Netherlands). Total distance moved and
time spent in center area were calculated accordingly.
Forced swimming test. A transparent cylinder (25 cm height × 10 cm
diameter) was ﬁlled up with water up to a height of 10 cm, as described
earlier.22 Fresh water was equivalent to the room temperature and
changed for individual mouse. The camera was oriented for horizontal
viewing. A sheet of cardboard was placed in-between the two cylinders so
that the mice could not see each other. The movement of mice was
recorded by software EthoVision 3.0 and divided into 3 kinds: immobility,
mobility and strong mobility. Duration of immobility time was recorded in
total 6 min.
Sucrose preference test. Mice were individually housed and given two
bottles of liquid: a bottle with plain water and the other one with 1%
sucrose. Bottles were reversed every 12 h. After 3 days of habituation, all
bottles were removed at 1000 hours. After 12 h water deprivation, mice
were given access to bottles of water and sucrose, in the reversed location.
The bottles were reversed again 1 h later and weighed on the following
morning. Sucrose preference was expressed as (Δ weight-sucrose)/
(Δ weight-sucrose +Δ weight-water) × 100.5
Circadian rhythm assessment. This experiment was performed in Hong
Kong University of Science and Technology, with 12:12 light/dark cycle
(L 0600 to 1800 hours). Mice were housed individually in cages with
running wheels linked to detectors.23 Day 1–10 was the habituation
period. On day 11, the dark cycle was advanced by 6 h (L 0000 to 1200
hours) and mice were allowed to re-entrain for another 10 days. Time
spent for adapting to the new light dark cycle was recorded. Average
wheel running activity in light phase and dark phase was calculated before
light dark shift (day 8 - day 10), and after light dark shift (day 18 - day 20).
Water and food were provided ad libitum. The wheel running activity was
recorded and analyzed using the Clocklab software (Actimetrics, Wilmette,
IL, USA).
Pavlovian fear conditioning. This experiment was performed as previously
described.24 Brieﬂy, on day 1, mouse received a training session of 13.5 min
in conditioning chamber (25 cm×25 cm×25 cm), where the mouse could
freely explore in the chamber. The training consisted of a habituation
period of 6 min, followed by 3 times of paired presentations of tone
(conditional stimuli) and foot shock (unconditional stimuli). The foot shock
(0.5 mA) was applied to the ﬂoor grid of the chamber during the ﬁnal 2s of
the tone (30s, 4 Hz, 80 dB). There was 2-min rest every time after the tone-
shock pairing. The chambers were wiped and cleaned with 70% ethanol
between training sessions. On day 2, fear conditioning to the context was
assessed by returning the mice to the same chamber for 8 min, without
tone or shock stimuli. On day 3, fear to the tone conditional stimuli was
assessed in novel chamber with explicit cue as day 1, in the absence of foot
shock. The chambers were cleaned with diluted creamy soap to remove
olfactory debris. The contextual and cued tests scheme was applied again
to the mice 1 week after the training. EthoVision XT7 (Noldus) detection
system was used and the videos were saved for later behavioral analysis.
A complete suppression of spontaneous locomotion and movements was
counted as freezing behavior.
Morris Water Maze. Morris Water Maze with automatic tracking system
was employed for assessing the spatial learning and memory as described
before.21 All the experimental procedures were performed within the light
cycle (0900 to 1300 hours). The mice were tested in three blocks of training
in 9 consecutive days: visible platform training, hidden platform training
and probe test. In trainings with platform, the mice were allowed to swim
to reach the platform for a maximum period of 1min. Otherwise they were
guided to the platform by the experimenter. In the visible platform test, no
external cue was applied. Mice were trained to reach the ﬂag-cued visible
platform for 2 days with 4 trials per day. The platform location and starting
position varied for each trial. In the hidden platform training, external cues
were hanged onto the wall of the room and the platform was immersed
into the opaque water with white non-toxic painting dye. Mice were
trained for 6 days with 4 trials per day and the starting position was in a
pseudorandom manner. Probe test was performed 1 day after the last
hidden platform training. During probe trials, experimental mice were
allowed to swim freely for 1min without platform placing inside the pool
but with same distal cues placed in hidden platform trainings. The starting
position is at the opposite side of the previous hidden platform location.
Escape latency to the platform was calculated as an evaluation of
performance of the mice to locate the target. The performance in probe
trial was expressed as time spent in the target quadrant with platform
location during hidden platform training. Swimming velocity in each trial
was also recorded. The value was calculated by EthoVision 3.0.
Chronic restraint stress model
Mice were housed individually during the whole experimental procedure.
For restraint stress groups, mice received a 2-h restraining treatment daily
(0800 to 1000 hours) for consecutive 7 days, in 50-ml conical tubes with
holes to maintain airﬂow. After each stress session, mice were returned to
their home cages. Mice in control group were handled for around 10 s and
returned to the home cage. Body weights were recorded daily before
experiment started. At 0800 hours on day 8, the exploratory activity and
anxiety-like behavior were monitored in the open ﬁeld test. On different
cohorts of mice, depressive-like behaviors were also studied in the forced
swimming and sucrose preference tests.25
Corticosterone measurement
Corticosterone levels in the circulation were measured to determine the
activity of the hypothalamic-pituitary-adrenal (HPA) axis in different lines of
mice. Mice were divided into two groups, home caged (resting) or stressed.
Blood samples from tail tip were collected between 0930 to 1130 hours.
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For home caged mice, blood was collected rapidly without disturbance
before mice removed from their cages. For stressed mice, blood samples
were collected immediately after 30-min restraint. Serum was separated by
centrifugation and stored at −20°C until assay. Corticosterone levels were
measured using the corticosterone ELISA kit (Assay Designs, Ann Arbor, MI,
USA) following the manufacturer’s instructions.
Drug treatment
Fluoxetine hydrochloride (Flx, Prozac) was administered to mice at a dose
of 10 mg kg− 1 body weight.26 Drugs were prepared freshly in vehicle (0.9%
saline) on the day of administration, whereas the control group received
the same amount of vehicle only. The animals were orally administered
with a feeding needle daily at the same periods of time (0900 to
1100 hours) over the course of 14 days with their body weights recorded
every day. On day 15, behavioral assessments were conducted at 0900 to
1100 hours, followed by ﬂuoxetine treatment. Bromodeoxyuridine (BrdU)
was administered four times a day after behavioral tests as described
above, followed by the last ﬂuoxetine treatment. Animals were killed 24 h
after the last BrdU administration.
BrdU labeling
BrdU labels the dividing cell populations by incorporating into replicating
DNA in place of thymidine. For cell proliferation analysis, mice received
four injections of BrdU (4 × 75 mg/kg, with 2-h intervals). Animals were
killed 24 h after the last BrdU administration.7 To determine the survival
and differentiation of newborn cells, mice were killed 4 weeks after the last
BrdU administration. Brains were collected for BrdU staining and analysis
accordingly.
Sample collection and analysis
Sample preparation. For immunohistochemistry, mice were anesthetized
with ketamine/xylazine (120 and 10 mg kg− 1, respectively) and transcar-
dially perfused. Brains were collected, followed by 4% paraformaldehyde
ﬁxation overnight at 4 °C, and were stored in 30% sucrose. Serial sections
were then cut (40 μm) through each entire hippocampus (Bregma − 1.22
to − 3.40 mm) using a freezing microtome. Every sixth section was kept for
immunohistochemistry.
Cell counting. Z-stack confocal images through the entire section were
collected using Zeiss 710 confocal microscope to distinguish single cells
within clusters. For BrdU and Ki67 staining, all staining-positive cells in the
granule cell layer and hilus were counted in each section. The total number
of BrdU- or Ki67-labeled cells per section (average of left and right dentate
gyrus, DG) was determined and multiplied by 6 to obtain the number of
total staining-positive cells per DG.7 For doublecortin (DCX), representative
images were taken at the middle of suprapyramidal blade of the granule
cell layer in each section. DCX-positive cells were categorized according to
the morphological grouping criteria described previously.27 DensityDCX
+cells =NDCX+cells/(widthentirely captured GCL × thicknessstacked image). More than
150 DCX-labeled cells were analyzed per animal. For double staining,
ﬂuorescence signals were visualized under Zeiss 710 confocal microscope.
Colocalization of BrdU with neuronal nuclear antigen (NeuN) or glial
ﬁbrillary acidic protein (GFAP) was examined using multiple planes for
each BrdU-positive cell on the z axis.
Immunocytochemistry and Western blot analysis
Fluorescent staining. After being rinsed with 1 × PBS, sections were
pretreated with blocking solution for 30min at room temperature. Sections
were incubated with primary antibodies in diluent at 4°C, for overnight.
After washing with 1 × PBS for 10min 3 times, sections were incubated
with secondary antibodies in PBS at room temperature, for 1 h.
3,3'-Diaminobenzidine staining. After being rinsed with 1 × PBS, sections
were quenched in 0.3% H2O2 at room temperature, for 30min. Sections
were blocked and incubated with the primary antibody at 4°C overnight,
and, after washing, exposed to biotinylated secondary antibodies at room
temperature, for 2 h. Immunoreactivity of samples using biotinylated
secondary antibodies was detected with VECTASTAIN Elite ABC kit (Vector
Laboratories, Burlingame, CA, USA).
Extra steps for BrdU staining. Antigen retrieval was achieved by boiling
sections in 10mM citrate buffer at pH 6.0 for 30min. Before blocking,
sections were exposed to 2N HCl for 30min for deoxyribonucleic acid
hydrolysis, rinsed with PBS and immediately neutralized in boric acid for
15min.
Western blot analysis. Hippocampi were collected and stored in −80°C
until further process. Hippocampus was collected and lysed in RIPA buffer
(150mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM
Tris-HCl pH 8.0, EDTA-free protease inhibitors, Roche) for Western blot
analysis. Homogenate was centrifuged at 12 000 r.p.m. at 4°C for 15min.
Supernatant was transferred to a new tube and protein concentration was
determined by BioRad protein assay. The volumes of the sample used were
adjusted to give equal loadings to each lane. Proteins were separated by
SDS-PAGE gel and transferred onto a polyvinylidene diﬂuoride membrane.
The membrane was blocked for 1h with 5% non-fat dry milk powder in
TBST buffer to eliminate non-speciﬁc binding sites. The membrane was
then incubated with primary antibody in blocking solution for overnight at
4°C Detection was performed with peroxidase-conjugated goat anti-mouse
or goat anti-rabbit antibody in 1:2500 dilution. Peroxidase activity was
revealed using the enhanced chemiluminescence method. Image J was
used for densitometric analysis of blots.
Antibodies used in immunohistochemistry were as follows: BrdU
(Ab6326, 1:1000, Abcam, Cambridge, UK), DCX (AB5910, 1:500, Millipore,
Billerica, MA, USA), NeuN (MAB377, 1:1000, Millipore), GFAP (Z0334, 1:5000,
DAKO, Glostrup, Denmark), pCREB (#9198, 1:1000, Cell Signaling Technol-
ogy, Danvers, MA, USA) and Ki67 (Ab15580, 1:1000, Abcam, Cambridge,
UK). Antibodies used in Western blot analysis included the following: Epac1
and Epac2 (kind gifts from Professor J Bos, 1:2000), PKA (Ab65013, 1:2000,
Abcam, Cambridge, UK), phospho-PKA (ABT58, 1:1000, Millipore), BDNF
(Sc-546, 1:500, Santa Cruz, Dallas, TX, USA) and α-tubulin (T9026, 1:10000,
Sigma-Aldrich, St. Louis, MO, USA).
Measurement of neurotransmitters using LC-MS/MS
Formic acid (0.5 M) was added to the spinal cord samples at a ratio of 5 ml
per gram tissue. Lysates were obtained by homogenization until no debris
were observed. The supernatant was collected under twice of centrifuga-
tion: 3000 r.p.m. at 4 °C for 15 min and 14 000 r.p.m. at 4 °C for 20 min.
Samples were kept at − 20 °C before liquid chromatography–electrospray
tandem mass spectrometry (LC-MS/MS) measurement was performed as
described previously.28
Subject recruitment and assessments
One hundred and forty Chinese AD patients with either NINCDS-ADRDA
diagnosis for probable AD, or DSM-IV TR criteria29 for AD, were recruited
for this study (mean age at study= 82.4 years, s.d. = 7.6; range= 65–97). The
patients were recruited through ﬁrst attendance at the psychiatric clinic of
the New Territories East Cluster hospitals and from either Old Age Home or
social centers in the community. Four hundred control subjects were
recruited from local elderly social residential centers and hostels for the
elderly in Hong Kong. Subjects with signiﬁcant sensory deﬁcits or known
neurodegenerative and psychiatric disorders were excluded. All subjects
underwent cognitive assessments, including Clinical Dementia Rating
(CDR),30,31 Cantonese version of the mini-mental state examination,32
Chinese version of the Alzheimer’s Disease Assessment Subscale—
Cognitive subscale33,34 and delayed recall of list learning test. AD patients
were further assessed by the Chinese version of NPI35 for the psychiatric
symptoms observed in AD. CDR is a standard instrument for the diagnosis
and evaluation of the overall severity level of dementia. This rating served
as the primary outcome/observation for the current study. In this study,
subjects with CDR 0 (not demented), 0.5 (very mild dementia) and 1 (mild
dementia) at baseline were recruited. NPI was used to assess the AD
patients’ neuropsychiatric symptoms in 12 different domains (delusions,
hallucination, aggressivity, depression, anxiety, elation, apathy, disinhibi-
tion, irritability, aberrant motor behavior, night-time behavior and appetite
disturbances). A score for each domain was computed using frequency ×
severity. During recruitment, the psychiatrists explained the procedure and
obtained the informed consent from the subjects and/or their caregivers.
The study has been approved by the Clinical Research Ethics Committee of
the Chinese University of Hong Kong.
Genetic analysis of Chinese AD patients
Genomic DNA was extracted from peripheral blood samples using a DNA
Extraction Kit according to the manufacturer’s instruction (Roche, Nutley,
NJ, USA). Two intronic polymorphisms (rs2072115 and rs2074533) in
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RAPGEF3 reported to be associated with anxiety and depression were
genotyped in this study.36 Polymorphisms for RAPGEF4 in the catalytic
domain were selected according to the available genotype information
from HapMap, and a set of 10 tagSNPs were selected using R2 algorithm
among SNPs with minor allele frequencies of at least 5% in Asians.37
Genotyping was performed using melting temperature (Tm) shift allele-
speciﬁc genotyping method.38 Brieﬂy, primers were designed to differ-
entiate the WT and mutant base of the SNP by the difference in Tm
between the products of the allele-speciﬁc PCR. After DNA ampliﬁcation,
the PCR product was subjected to melting curve analysis using the Roche
LightCycler 480 Real-Time PCR System (Roche Applied Science, Penzberg,
Germany), and the base of the SNP was distinguished by the melting
temperature.
Statistical analysis
Deviations from the Hardy–Weinberg equilibrium for genotypes at individual
loci were assessed by using Pearson χ2. Statistical analysis of genotype
distribution between groups of subjects with different CDR was performed
by χ2-tests. The NPI score was compared among subjects with different
genotypes by Student’s t-test. For all the animal experiments, sample sizes
were chosen to ensure adequate power to achieve enough statistical power
based on the published articles with the studies and behavioral tests
conducted, which are similar to the present study. For the mouse behavioral
tests, mice that displayed abnormal behaviors such as seizures immediately
before or during the behavioral test would be excluded from the analysis. In
animal studies, two-tailed Student’s t-test or one-way analysis of variance
was used for single-factor experiments involving two or more than two
groups. For experiments comprising multiple factors, a two-way analysis of
variance was used, with post hoc analysis (Tukey’s multiple comparisons test,
unless otherwise stated) between subgroups. A signiﬁcance level was set to
0.05 for all statistical analyses. Randomization and blinding were not used for
animal studies. The data were analyzed using SPSS 17.0 (IBM, Chicago, IL,
USA) or Prism 6.01 (GraphPad Software, San Diego, CA, USA). Graphs
showing the means and s.e.m. were graphed using Prism.
RESULTS
Epac2− /− mice exhibit anxiety- and depressive-like behaviors
under normal conditions
To assess the locomotor activity and anxiety-related behavior, WT,
Epac1− /−, Epac2− /− and Epac1− /−;2− /− mice were placed in a
novel open ﬁeld for 1 h. Epac2− /− mice showed a higher
locomotor activity, indicated by the longer distance moved, and
the less time spent in the center area (Figure 1a). Epac1− /−;2− /−
mice, but not Epac1− /− mice, showed similar hyperactive and
anxiety-like behaviors to those of Epac2− /− mice (data not shown),
suggesting that these phenotypes may be attributed to the
absence of Epac2. To determine whether the hyperactive
phenotype of Epac2− /− mice was triggered by novel environment
or constantly exhibited, the locomotor activity on running wheel
under different lighting conditions was evaluated (Figure 1b). No
signiﬁcant difference was observed between the WT and Epac2− /−
mice in terms of the time for re-entrainment to light–dark cycle
shift, which indicated that normal circadian behavior could be
maintained in the absence of Epac2 (Figure 1c). Interestingly,
Epac2− /− mice showed a signiﬁcantly higher wheel-running
activity in the light phase but not in the dark phase (Figure 1d).
The total wheel-running revolution of Epac2− /− mice was similar
to that of WT mice (data not shown), but with less precise and
increased fragmentations (Figure 1b). This daily activity rhythm of
Epac2− /− mice was comparable to those that had been exposed
to chronic stress.39 To better understand the role of Epac2 in
emotional behavior, we employed chronic restraint stress (CRS)
model exhibiting hyperlocomotion and anxiety-like behavior40 as
a positive control (Figure 1e). Restraint stress resulted in higher
serum corticosterone levels in all groups; however, there were no
signiﬁcant differences among the three genotypes, whether in
resting or stressed condition (Figure 1f). In the open ﬁeld test, CRS
WT mice showed less time spent in the center area and increased
locomotor activity. Epac2− /−mice, similar to CRS WT mice, exhibited
less time spent in the center area and increased locomotion under
control condition, compared with that of WT mice (Figure 1g). In the
forced swimming test, Epac2− /− mice displayed aggravated
behavioral despairs, as indicated by the increased immobility time
compared with those of WT mice under normal condition and the
difference was further heightened by CRS (Figure 1 h). In the
sucrose preference test, Epac2− /− mice showed reduced preference
to sucrose, indicating anhedonia-like behavior, when compared
with that of control WT mice (Figure 1i). In all of these behavioral
tests, Epac1− /− mice exhibited similar phenotype to those of WT
mice. Taken together, Epac2 deﬁciency induced hyperactivity,
anxiety, anhedonia and depression phenotypes in mouse models,
indicating a crucial role of Epac2 in emotional controlling.
Epac2− /− mice with normal spatial learning and memory exhibit
deﬁcit in fear conditioning
Among the variety of brain structures responsible for controlling
emotional response to aversive stress, hippocampus and amyg-
dala are two of the few brain structures that are pivotal in most
Figure 1. Epac2− /− mice exhibit anxiety- and depressive-like behaviors. (a) Results of the open ﬁeld test in wild-type (WT) and Epac2− /− mice.
The time spent in the center area and the distance moved during a 1-h period in the open ﬁeld were measured (for time spent in center,
*Po0.05, **Po0.01 by unpaired t-test between WT and Epac2− /−mice; for distance moved, genotype effect F1, 168= 65.87, Po0.0001 by two-
way analysis of variance (ANOVA), *Po0.05, **Po0.01 by Sidak’s multiple comparisons between WT and Epac2− /− mice, N= 8). (b) Wheel-
running activities of WT and Epac2− /− mice were showed in representative actograms. The light–dark (LD) cycle was shifted from 0600-1800
to 0000-1200 hours on day 11. Synchronization of the internal circadian clock to the environment LD signal (re-entrainment) happened
several days later (arrowheads). (c) The average time for re-entrainment was calculated and presented in the bar chart (no signiﬁcant
difference was observed by unpaired t-test, N= 11). (d) Wheel-running activity was calculated in light and dark phases, before (days 8–10) and
after (days 18–20) the LD cycle shift, respectively (for LD shift effect, F1, 40= 129, Po0.05; for genotype effect, F1, 40= 9.585, Po0.01 by two-
way ANOVA. *Po0.05 indicates post hoc comparison between genotypes, N= 11). (e) The schematic representation of the chronic restraint
stress experimental procedure. Mice of WT, Epac1− /− and Epac2− /− were subjected to either regular handling (CON) or chronic restraint stress
(CRS), followed by the open ﬁeld, forced swimming or sucrose preference test. (f) Restraint stress resulted in higher corticosterone levels in
mouse serum, with no signiﬁcant difference among the three genotypes. Blood samples were collected from tail tips of mice in the home
cage (resting) or after a 30-min restraint stress (stressed). Corticosterone levels in serum (ng ml− 1) were measured (for stress effect, F1,
16= 129.0,
###Po0.0001; for genotype effect, F2, 16= 0.02334, P= 0.9770 by two-way ANOVA, N= 3-5). (g) WT, Epac1− /− and Epac2− /− mice, in
CON or CRS groups, were monitored in the open ﬁeld. The time spent in the center area and the distance moved for the ﬁrst 10 min were
observed (for the time spent in the center, stress effect: F1, 46= 3.688, P= 0.0610; genotype effect: F2, 46= 4.454, Po0.05. For the total distance
moved, stress effect: F1, 46= 4.067, Po0.05; genotype effect: F2,46= 4.753, Po0.05. *Po0.05 and **Po0.01 indicate post hoc comparison
between genotypes, #Po0.05 and **Po0.01 indicate post hoc comparison between control and stressed groups, N= 8–10). (h) In the forced
swimming test, the immobility time during the 6 min was plotted (stress effect: F1,41= 2.358, P= 0.1323; genotype effect: F2,41= 15.24,
Po0.0001. *Po0.05 and **Po0.01 indicate post hoc comparison between genotypes, N= 7–10). (i) In the sucrose preference test, mice were
given one bottle of water and one bottle of 1% sucrose solution. Their preference to sucrose was expressed as (Δweightsucrose)/(Δweight-
sucrose+Δweight-water) × 100 (stress effect: F1,30= 1.077, P= 0.3076; genotype effect: F2,30= 2.357; P= 0.1120. *Po0.05 indicates post hoc
comparison between genotypes, N= 5–8).
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types of aversive learning.41 Two widely used behavioral tasks for
evaluating learning and memory were performed on WT and
Epac2− /− mice. Pavlovian fear-conditioning test assesses the
learning ability to anticipate danger by associating neutral stimuli
(context or tone) with aversive events (foot shock). Conditioning
to a tone involves projections from the auditory system to
amygdala, and conditioning to environment and other contextual
cues involves the hippocampus and amygdala.42 Compared with
the 6 min pre-shock period, foot shock largely increased freezing
in animals across all intervals after stimuli, and there were no
Open field test
Chronic restraint stress
Behavioral test
Death
Day0 Day7 Day8 Day9
Open field test
Forced swimming test Sucrose preference test
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signiﬁcant differences among groups of different genotypes
(Figure 2a). Interestingly, on the following 2 days, Epac2− /− mice
showed signiﬁcantly reduced freezing response in the contextual
test (in the same chamber without tone) and the cued test (in a
novel chamber with same tone patterns at the day of training).
The deﬁcit in fear conditioning suggested that Epac2 deﬁciency
led to dysfunction of the amygdala and/or hippocampus, which
might be correlated to the anxiety and depressive-like phenotype
of Epac2− /− mice. On the other hand, in the Morris Water Maze,
Epac2− /− mice showed normal spatial learning performance in six
consecutive days of the hidden platform training, as well as in the
probe test without platform on day 7 (Figure 2b). Western blot
analysis revealed that Epac2 was highly expressed in the
hippocampus of WT mice and yet absent in that of Epac2− /−
mice. Neither compensatory upregulation of Epac1 or PKA nor
change of PKA phosphorylation (Ser96) was observed in the
Epac2− /− hippocampus (Figures 2c–h).
Epac2 deletion leads to impaired hippocampal neurogenesis and
decreased progenitor cell proliferation
The role of neurogenesis in pathogenesis of anxiety and
depressive disorders has been widely recognized.5,43 Besides,
ablation of hippocampal neurogenesis led to impaired contextual
(Ser96)pPKA
PKA
Fear conditioning learning
Epac1
Epac2
PKA
-tubulin
WT Ep
ac1
-
/-
Epa
c2
-
/-
WT Epac2
Morris water maze
Figure 2. Epac2− /− mice with normal spatial learning and memory exhibit deﬁcit in fear conditioning. (a) Epac2− /− mice showed impaired
cued and contextual fear memory retrieval. Percentages of the freezing behavior were determined during pre-shock period (free exploration),
FC period (all of the 90-s post-shock intervals following the foot shock stimuli) and contextual/cued tests performed on the following 2 days
(*Po0.05, **Po0.01 by one-way analysis of variance (ANOVA), N= 9–11). (b) Mice were trained in the hidden platform for 6 days (four
trainings per day). Escape latency was calculated as the time from the start to the moment when mice reached the platform. No signiﬁcant
difference was found in escape latency at individual time points in the hidden platform training by unpaired t-test. Probe test was conducted
1 day after the hidden platform training. Percentages of the time spent in the 4 quadrants (quadrant 2 as target quadrant in the hidden
platform training) were measured. No signiﬁcant difference was found by unpaired t-test. (c) Western blots of Epac1, Epac2, protein kinase A
(PKA) and the internal control α-tubulin in the hippocampus of wild-type (WT), Epac1− /− and Epac2− /− mice. (d-f) Epac1, Epac2 and PKA
expression levels in the hippocampus of WT, Epac1− /− and Epac2− /− mice were calculated as the ratios of target proteins to α-tubulin
intensities, and data of other genotypes were normalized to that of WT (no signiﬁcant difference was observed by one-way ANOVA, N= 6). (g-
h) Western blots of phosphor-PKA (Ser96) and PKA in the hippocampus of WT and Epac2− /− mice. Ratio of phosphor-PKA to PKA was
calculated, and data were normalized to those of WT (no signiﬁcant difference was observed by unpaired t-test, N= 4–5).
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fear conditioning but not spatial learning.4 These behavioral
phenotypes were also observed in the Epac2− /− mice. Therefore,
Epac2 may be required for hippocampal neurogenesis that is
crucial in regulating behavioral responses under stress condition.
To assess this hypothesis, multiple doses of the thymidine analog
BrdU were administered to WT and Epac2− /− mice, followed by
examination of the cell proliferation in the hippocampus of WT
and Epac2− /− mice (Figure 3a). Twenty-four hours after the last
BrdU injection, less BrdU-positive (BrdU+) cell clusters were
present in the subgranular zone of DG in Epac2− /− mice than
those of WT mice (Figures 3b and c). More than 70% of these
proliferating cells differentiated further into neuroblasts and
immature neurons expressing the marker of DCX (Figure 3d).
Meanwhile, we observed a presence of empty regions where no
DCX+ cells were found in Epac2− /− DG. To better understand the
observed condition, a morphological categorization method was
adopted27 (Figure 3e), so that the density of total DCX+ could be
quantiﬁed and the cell phases (proliferative, intermediate or
postmitotic) be distinguished at the same time. Within the
identical area, the number of DCX+ cells was signiﬁcantly
decreased in Epac2− /− mice compared with that of WT mice
(Figure 3f). Although cell numbers in each category were reduced,
the most obvious difference came from type B (DCX+ cells with
short and plump process) and type E (DCX+ cells with one strong
dendrite branching in the molecular layer; Figure 3g). These data
indicated that there was impairment in the neuronal progenitor
cells at proliferative and postmitotic stages in the absence of
Epac2. The expression of endogenous proliferative marker Ki67
was also signiﬁcantly reduced in the DG of Epac2− /− mice
(Figures 3h and i). Taken together, the results of BrdU labeling,
DCX and Ki67 staining results consistently suggested the
impairments of hippocampal progenitor cell proliferation and
neurogenesis in Epac2− /− mice. Survival and differentiation of the
BrdU+ cells were examined 28 days after the last injection of BrdU
(Figures 3j–l). Note that the number of BrdU+ cells was largely
decreased when compared with that at 24 h post injection,
whereas no signiﬁcant difference was observed between WT
and Epac2− /− mice (Figure 3k). The cell fate of BrdU+ cells
was also determined by double staining with BrdU and
neuronal marker NeuN or astrocytic marker glial ﬁbrillary
acidic protein (Figure 3j). More than 60% of the BrdU+ cells
differentiated into neurons as indicated by BrdU and NeuN co-
staining. No signiﬁcant difference in the percentage of BrdU+
neurons or astrocytes was found between WT and Epac2− /− mice
(Figure 3l). These data demonstrated that Epac2 deﬁciency did not
affect the survival and differentiation of adult-born cells in DG
in vivo.
SSRI treatment increases hippocampal cell proliferation and
ameliorates anxiety-like behavior in Epac2− /− mice
Antidepressant ﬂuoxetine, a selective serotonin reuptake inhibitor,
promotes hippocampal neurogenesis in adult rodents,7 and it
mainly targets early amplifying progenitor cells.26 As a defect in
amplifying progenitor cells was observed in Epac2− /− mice with
anxiety and depression, we hypothesized that these behavioral
phenotypes of Epac2− /− mice could be rescued by neurogenic
ﬂuoxetine treatment. WT and Epac2− /− mice were chronically
administered with ﬂuoxetine for 2 weeks (Figure 4a). To examine
the drug effect on neurogenesis, BrdU was administered 24 h
before killing the mice. Representative photomicrographs and
quantitative data showed that in the vehicle-treated group
Epac2− /− mice had less BrdU+ cells than WT mice. BrdU+ cells
in the subgranular zone of WT mice were slightly increased after
ﬂuoxetine treatment, whereas BrdU+ cells in ﬂuoxetine-treated
Epac2− /− mice were signiﬁcantly reversed (Figures 4b and c).
Fluoxetine signiﬁcantly ameliorated anxiety-like behavior of
Epac2− /− mice, indicated by increased time spent in the center
area of the open ﬁeld, although no positive effect was observed in
the ﬂuoxetine-treated WT mice. Meanwhile, the hyperactive
phenotype of Epac2− /− mice was moderately reversed by
ﬂuoxetine treatments (Figure 4d). Similarly, vehicle-treated
Epac2− /− mice showed signiﬁcantly higher immobility than their
WT counterparts, and ﬂuoxetine only showed marginal effects in
either WT or Epac2− /− mice (Figure 4e). The cAMP-CREB cascade
profoundly contributes to adult neurogenesis and to SSRI-
mediated neurogenesis.44 In agreement with the neurogenic
effect, administration of SSRI signiﬁcantly increased the
expression of pCREB (Ser133) in the hippocampal lysates of WT
and Epac2− /− mice (Figure 4f). Likewise, BDNF proteins were
signiﬁcantly elevated in ﬂuoxetine-treated Epac2− /− mice, and a
trend of increase was also observed in WT mice (P= 0.0645,
Figures 4g and h).
Epac2 deﬁciency leads to reduced GABA concentrations in the
hippocampus
To investigate the potential role of Epac2 in regulating major
neurotransmitters, concentrations of GABA, dopamine, norepine-
pherine, glutamate, serotonin and serotonin metabolite (5-
hydroxyindoleacetic acid, 5-HIAA) were determined by LC-MS/
MS in the hippocampal homogenates simultaneously (Table 1,
N= 5-6).28 The serotonin (5-HT) turnover rate was calculated as the
ratio of 5-HIAA/5-HT. Epac2− /− mice showed the normal level of 5-
HT and 5-HIAA, and maintained the normal 5-HT turnover rate in
the tissue homogenates of hippocampus, indicating that the
synthesis and elimination of 5-HT might not be affected by
deleting the Epac2 gene. Similarly, dopamine, norepinephrine and
glutamate concentrations in the Epac2− /− hippocampus were
comparable to those of WT. Interestingly, the GABA concentration
in hippocampal homogenates from Epac2− /− mice
(1157.52 ng ml− 1) was signiﬁcantly lower (~15%) than that in the
WT mice (1334.36 ng ml− 1), suggesting a critical role of Epac2 in
modulating GABAergic neurons in the hippocampus. Besides, we
measured GABA levels in the hippocampus of Epac2− /− mice
treated with vehicle or ﬂuoxetine. Surprisingly, the reduced GABA
level in Epac2− /− mice did not get corrected by chronic ﬂuoxetine
treatment (Supplementary Figure 1).
Non-coding RAPGEF4 SNPs are associated with cognitive decline
and mood disturbance in AD patients
Previously reported SNPs in RAPGEF3 gene36 were screened and
no signiﬁcant association between these SNPs and the risk of AD
or NPI score was observed (data not shown). Interestingly,
signiﬁcant differences in genotype distribution for rs3820841
(intron 17) and rs3769219 (intron 23) in RAPGEF4 were observed
among normal control subjects (CDR 0), subjects with very mild
dementia (CDR 0.5) and AD patients (CDR 1; Table 2). There was no
difference in genotype distribution of RAPGEF4 rs17746510 (intron
22) between normal subjects and AD patients; however,
signiﬁcant difference was observed between subjects with CDR
0.5 and CDR 1. The NPI score in different domains was compared
among AD patients with different genotypes (Table 3). AD patients
with GG genotype of rs17746510 was associated with a higher NPI
score in apathy and mood disturbance, but not in domains in
behavior, psychosis and sleep, suggesting that they encountered
more complains in emotion-related domains.
DISCUSSION
There is a close inter-relationship between mood and cognition,
both of which have equally disabling effects on patients.
Understanding the common molecular and cellular mechanisms
underlying the progression of cognitive decline and concomitant
affective traits, such as anxiety, apathy and depression, is critical in
developing therapies for patients with mood disorders or
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neurodegenerative diseases such as AD. In the present study, we
showed that Epac2 deletion, but not Epac1 deletion, led to
emotional disturbance, indicated by anxiety, hyperactivity, anhe-
donia and depressive-like behaviors in mouse models. Epac2− /−
mice exhibited normal spatial learning but reduced fear con-
ditioning. On the basis of the observation that SSRI treatment
upregulated hippocampal neurogenesis and rescued the beha-
vioral deﬁcits of Epac2− /− mice, we conclude that these
abnormalities in emotion and cognition of Epac2− /− mice were
associated with impaired neurogenesis, especially neural pro-
genitor cell proliferation in the DG. Furthermore, the abnormal
emotional behavior and neurogenesis impairment were
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associated with a mild deﬁcit of GABA content in the hippocam-
pus of Epac2− /− mice. Finally, we showed association of several
polymorphisms in RAPGEF4 with cognitive decline and mood
disturbance in AD patients.
Epac2 deﬁciency induced emotional disturbance and cognitive
impairment in mouse model
Altered expression and activation of Rap1 and Epac2 were shown
in a post-mortem study on depressed suicide victims,15 but the
underlying mechanism is poorly understood because of the lack of
clinical samples. In the present study, in vivo animal study was
performed by using Epac knockout mice. Epac2− /− mice were
highly stress-reactive, mimicking patients with depression and
comorbid anxiety. In the open ﬁeld test, Epac2− /− mice showed
anxiety-like phenotype, similar to that of WT mice exposed to
chronic mild stress. This phenotype was also observed in
Epac1− /−;2− /− mice, but not in Epac1− /− mice (data not shown).
To further conﬁrm our observation, diurnal wheel-running activity
of mice in their home cages was recorded, as stressed mice have
been shown to display a higher percentage of wheel-running
activity in the light phase as well as fragmented wheel-running
pattern.39 Similar to stressed mice, Epac2− /− mice displayed a
signiﬁcantly higher activity during the light (inactive) phase,
although no such difference was observed during the dark (active)
phase compared with WT mice. These data suggested that Epac2
might have a role in anti-anxiogenic effects under mild stressor,
such as a novel environment and altered lighting. Our ﬁnding was
not in agreement with other studies in which Epac2− /− mice did
not show anxiety-like behavior in the open ﬁeld test.45,46 These
behavioral discrepancies may because of the intrinsic factor, like
mouse strain, and the environmental factors such as lighting
conditions.47 On the other hand, disturbance to the circadian
timekeeping system is closely linked with mood disorders and
cognitive dysfunction.48 Recently, cAMP/Epac signaling was
reported to sustain the circadian rhythm pacemarker in the
suprachiasmatic nuclei, potentially by activating CREB and Per
transcription.49 In the present study, the abnormal circadian
rhythm or re-entrainment after light–dark cycle shift in Epac2− /−
mice was undetected, indicating that Epac1 and Epac2 may have
redundant roles or functional compensation in physiological
circadian clockwork (Supplementary Figure 2).
Furthermore, Epac2− /− mice, but not Epac1− /− mice, showed
despair and apathy behaviors in the forced swimming and sucrose
preference tests, supporting a vital role of Epac2 in emotional
appraisal. Abnormal stress hormone corticosterone levels may be
a potential explanation of anxiety,50 anhedonia and behavioral
despair.51 Epac has been reported to couple adrenocorticotropic
hormone-mediated cortisol secretion from the adrenal zona
fasciculate.52 In the present study, no signiﬁcant difference in
serum corticosterone levels was observed among the three
genotypes, either in the resting or stressed condition. Besides,
the weight of adrenal glands of Epac2− /− mice was similar to that
of WT (data not shown). These results suggested that the anxiety-
and depressive-like phenotypes induced by Epac2 deletion might
be independent of the basal corticosterone maintenance and its
secretion under stress. However, we do not exclude the potential
involvement of Epac2 in the negative feedback regulation of the
HPA axis regarding its role in hippocampal neurogenesis.5
Cognition interplays with stress pathogenesis because of the
common underpinning cerebral regions, such as hippocampus
and amygdala.41 Previous studies have showed that the
Epac agonist, 8-pCPT-2’-O-Me-cAMP, improves hippocampus-
dependent conditioned memory retrieval.17,18 However, such
Epac agonist activates both Epac1 and Epac2.53 Here we observed
that Epac2, but not Epac1, was required for contextual and cued
fear-conditioning memory retrieval, indicating that the effect of
Epac agonist previously found in hippocampus-dependent fear
memory retrieval was because of the activation of Epac2. Besides,
Epac2− /− mice showed reduced freezing behavior in cued and
contextual tests 7 days after training, compared with WT mice,
indicating that Epac2 not only has a role in intermediate-term
memory retrieval but also potentially has a lasting effect on
consolidation (Supplementary Figure 3). Such observation partially
contradicts previous report that knockdown of Epac2 by
intrahippocampal short interfering RNA transfection did not alter
freezing behavior 17 days after the training.54 We speculated that
this discrepancy might have been resulted from either the degree
(knockdown versus knockout) of loss of Epac2 function, or other
differential experimental schemes. The normal performance in the
Morris Water Maze test indicated that such memory deﬁcits of
Epac2− /− mice are speciﬁcally related to emotion and fear.
Accordingly, long-term potentiation was triggered and recorded
in CA3–CA1 of cultured hippocampal slices and no signiﬁcant
difference was observed between WT and Epac2− /− brain slices
(data not shown). One of the interpretations of these two results is
that Epac2 may inﬂuence learning and memory primarily in tasks
that involve signiﬁcant emotional arousal or coactivation of the
hippocampus and the amygdala, which is supported by the
relatively high expression level of Epac2 in the hippocampus and
amygdala in humans.14 Another interpretation based on the
difference in nature of these two learning tests is that contextual
conditioning learning is induced during exposure to a novel
environment, whereas spatial learning in the Water Maze Test
occurs in the same environment repetitively. Novelty exploration
leads to the enhanced long-term potentiation in the DG,55,56
which is suggested to involve distinct long-term potentiation in
the medial perforant path/DG connection mediated by new
neurons.4 In fact, a lower rate of neurogenesis in the DG has long
been shown to correlate with hyperlocomotor activity in a novel
environment.57 Such hypothesis is in line with our other ﬁndings
that Epac2− /− mice exhibited hyperactivity and anxiety in the
open ﬁeld test, in which the animals were introduced to a novel
Figure 3. Epac2− /− mice show decreased neural stem/progenitor cell proliferation. (a) The schematic representation of the procedure of
bromodeoxyuridine (BrdU) labeling. Brain samples were collected 24 h after the last BrdU injection and were co-stained with BrdU and
doublecortin (DCX). (b) Representative photomicrographs of the adult dentate gyrus (DG) from wild-type (WT) and Epac2− /− mice with BrdU
(red) and DCX (green) staining. The majority of the BrdU-positive (BrdU+) cells were located in the subgranular zone of DG. Arrows and insets
indicate typical dividing BrdU+ cells with DCX staining (scale bars: 100 μm; inset, 20 μm). Quantitative data were showed as (c) the number of
BrdU+ cells and (d) the percentage of BrdU/DCX double-stained cells in BrdU+ cells in the DG of WT and Epac2− /− mice (*Po0.05 by unpaired
t-test, N= 3). (e) DCX-positive (DCX+) cells (red) were categorized and counted according to a schema of dendritic morphology (adopted from
Plümpe T et al.27). The six categories, through A to F, represented the development of DCX+ cells in different stages. Quantitative data were
showed as (f) the total DCX+ cell density and (g) the density of DCX+ cells from different categories in the granule cell layer (*Po0.05,
**Po0.01 by unpaired t-test, N= 6). (h) Representative photographs and (i) quantitative data showing Ki67-positive (Ki67+, red) cells in the DG
of WT and Epac2− /− mice (scale bar: 100 μm, *Po0.05 by unpaired t-test, N= 4). (j) Fate and differentiation of DG BrdU+ cells 28 days after last
BrdU injection. Representative confocal microscopic images of cells labeled with BrdU (green) and neuronal nuclear antigen (NeuN, red) or
glial ﬁbrillary acidic protein (GFAP, red) in the DG granule cell layer (scale bar: 20 μm). (k) Quantitative data show the number of BrdU+ cells
4 weeks after the BrdU labeling. (l) Quantitative data show the percentage of NeuN+/BrdU+ or GFAP+/BrdU+ cells 4 weeks after the BrdU
labeling. Note that most of BrdU+ cells differentiate into neurons (no signiﬁcant difference was found by unpaired t-test, N= 4–6).
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environment, and Epac2− /− mice had impaired hippocampal
neurogenesis.
Epac2 deﬁciency induced suppression on hippocampal
neurogenesis
Epac2 deletion negatively regulated hippocampal neural progeni-
tor proliferation in vivo, which had a pivotal role in behavioral
responses to novelty, emotional controlling and cognitive func-
tions under the novel and stressful condition.4,5,58 To assess
whether the abnormal behaviors of Epac2− /− mice might be
related to impaired neurogenesis, the antidepressant with
neurogenic effects, ﬂuoxetine, was administered to examine
whether this could rescue the behavioral defect in Epac2− /−
mice. As expected, ﬂuoxetine treatment ameliorated retarded
hippocampal neurogenesis, indicated by the increased BrdU
labeling in DG. Fluoxetine treatment on Epac2− /− mice signiﬁ-
cantly reversed anxiety-like behavior indicated by the increased
time spent in the center area of an open ﬁeld. After a short period
of ﬂuoxetine treatment, the Epac2− /− group exhibited a trend of
decreased hyperactivity in the open ﬁeld test and immobility in
Day0 Day14 Day17
Death
BrdU
Behavioral test
FLX (10mg/kg, ig., 2 weeks)
WT Epac2
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  WT                                                        Epac2
VEH
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  WT                                     Epac2
BDNF
-tubulin
VEH               FLX             VEH               FLX
Forced swimming test
Figure 4. Selective serotonin reuptake inhibitor (SSRI) treatment with neurogenic effect ameliorated anxiety-like behavior in Epac2− /− mice.
(a) Timeline of drug treatment, behavioral tests and bromodeoxyuridine (BrdU) labeling. (b) Representative photomicrographs and (c)
quantitative data show the BrdU+ cells in the dentate gyrus (DG) of wild-type (WT) or Epac2− /− mice with vehicle or ﬂuoxetine treatment
(treatment effect: F1,16= 5.078, Po0.05; genotype effect, F1, 16= 10.57, Po0.01; *Po0.05 indicates post hoc comparison between genotypes,
#Po0.05 indicates post hoc comparison between vehicle and ﬂuoxetine-treated groups; N= 3–5, scale bar: 50 μm). (d) Open ﬁeld test and (e)
forced swimming test were conducted after a 2-week saline (VEH) or ﬂuoxetine (FLX) treatment (for time spent in the center, treatment effect:
F1,16= 0.8835, P= 0.3612; genotype effect: F1,16= 2.780, P= 0.1149. For the distance moved, treatment effect: F1,16= 5.563, Po0.05; genotype
effect: F1,16= 18.98, Po0.001. N= 5 in the open ﬁeld test. For the forced swimming test, treatment effect: F1,34= 2.057, P= 0.1607; for
genotype effect, F1,34= 9.183, Po0.01; N= 9-10. *Po0.05 indicates post hoc comparison between genotypes, ##Po0.01 indicates post hoc
comparison between vehicle and ﬂuoxetine-treated groups). (f) Representative photomicrographs of pCREB staining in the DG from vehicle or
ﬂuoxetine-treated WT or Epac2− /− mice (N= 3, scale bars: 100 μm; inset, 20 μm). (g) Brain-derived neurotrophic factor (BDNF) expression levels
in the hippocampus of vehicle or ﬂuoxetine-treated mice were detected by Western blot analysis. (h) α-tubulin was used as the internal
control. Data from other groups were normalized to vehicle-treated WT group (treatment effect, F1,16= 11.18, Po0.01; genotype effect,
F1,16= 0.3050, P= 0.5884;
#Po0.05 indicates post hoc comparison between vehicle and ﬂuoxetine-treated groups; N= 5–6).
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the forced swimming test; therefore, it is postulated that a
prolonged treatment or higher dosages of ﬂuoxetine would have
shown a signiﬁcant effect.59 The data above indicated that the
anxiety and depressive behaviors of Epac2− /− mice were
associated with the impaired neurogenesis. Besides, no signiﬁcant
change of behaviors in WT mice following the identical
antidepressant treatment was observed. We speculated that
ﬂuoxetine treatment reduced anxiety on stressed but not on
normal animals,60 similar to the report that antidepressants have
profound mood-altering effects in patients rather than in healthy
individuals.61 The mechanisms of ﬂuoxetine action involve multi-
ple molecular pathways, of which the most well studied is through
activation of serotonergic receptors,62 cAMP-CREB signaling
pathway44 and increased production of BDNF.63 In agreement
with the above studies, we showed that the anxiolytic and
neurogenesis effect of ﬂuoxetine on Epac2− /− hippocampus was
associated with upregulation of pCREB (Ser133) and BDNF
expression. Although Rit, an effector of Epac proteins, can lead
to activation of the CREB by phosphorylation,64 and the Epac
agonist can trigger CREB phosphorylation in suprachiasmatic-
nucleus brain slices,49 we did not ﬁnd differences in baseline
pCREB or BDNF levels between WT and Epac2− /− hippocampus,
indicating the cAMP/CREB/BDNF pathway in hippocampus
remained intact in the absence of Epac2.
There are several potential explanations for the mechanistic role
of Epac2 in regulating hippocampal neurogenesis. First, the Rap1/
B-Raf/ERK signaling pathway downstream to various growth factor
receptor tyrosine kinases controls cell proliferation, differentiation,
migration and survival.65,66 Mice with B-Raf mutation show
reduced proliferation in the developing cortex of E14.5.66
Although the perinuclearly localized endogenous Epac1 could
not mediate Rap1-induced ERK activation, translocation of Epac1
to the plasma membrane by adding a membrane-targeting motif
allows it to activate the Rap1/ERK pathway.67 On the other hand,
the presence of N-terminal cAMP-binding domain in Epac2
enables it to localize to the plasma membrane,68 which suggests
a potential role of Epac2 in regulating the Rap1/B-Raf/ERK
pathway.
Furthermore, although a lower number of neural progenitor
cells was initially produced in the adult hippocampus of Epac2− /−
mice, eventually no difference between genotypes was shown
with regard to the number of these cells that were able to survive
till 28 days after BrdU labeling. Similar to our observation, the
discrepancy between proliferation and neuronal cell survival,
indicated by short-term and long-term BrdU labeling, was also
reported by other groups.57,69 There are two potential explana-
tions to this phenomenon. First, a large portion of excess neurons
is eliminated through apoptosis during neurogenesis.70,71
Table 1. LC-MS/MS measurement of neurotransmitters in the
hippocampus of WT and Epac2− /− mice
WT Epac2− /− P-value
5-HT (ng ml− 1) 1.31772 1.32372 0.8792
5-HIAA (ng ml− 1) 22.6468 22.8780 0.3113
5-HT turnover 17.4129 17.3516 0.9270
Norepinephrine (ng ml− 1) 189.196 176.364 0.2178
Dopamine (ng ml− 1) 17.8403 17.9343 0.4695
Glutamate (ng ml− 1) 7895.45 7557.04 0.3144
GABA (ng ml− 1) 1334.36 1157.52 *0.0258
Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; LC-MS/MS,
liquid chromatography–electrospray tandem mass spectrometry; WT,
wild type. *Po0.05 by unpaired t-test between WT and Epac2− /− mice.
Table 2. Signiﬁcant association between RAPGEF4 SNPs and cognitive decline
RAPGEF4 SNP Subjects Genotype P-value
rs3769219 TT TC CC
CDR 1 0 (0%) 12 (9.4%) 115 (90.6%) **0.003
CDR 0.5 0 (0%) 25 (22.5%) 86 (77.5%)
CDR 0 0 (0%) 45 (24.5%) 139 (75.5%)
rs3820841 TT TC CC
CDR 1 35 (25.4%) 62 (44.9%) 41 (29.7%) **0.001
CDR 0.5 37 (22.8%) 49 (30.2%) 76 (46.9%)
CDR 0 42 (17.7%) 71 (30.0%) 124 (52.3%)
rs17746510 TT TG GG
CDR 1 48 (34.8%) 72 (52.2%) 18 (13.0%) 0.167
CDR 0 93 (39.2%) 101 (42.6%) 43 (18.1%)
CDR 1 48 (34.8%) 72 (52.2%) 18 (13.0%) *0.036
CDR 0.5 62 (38.5%) 63 (39.1%) 36 (22.4%)
Combined
CDR 1 48 (34.8%) 72 (52.2%) 18 (13.0%) 0.13
CDR 0.5 62 (38.5%) 63 (39.1%) 36 (22.4%)
CDR 0 93 (39.2%) 101 (42.6%) 43 (18.1%)
Abbreviations: CDR, Clinical Dementia Rating; SNP, single-nucleotide polymorphism. *Po0.05, **Po0.01 by χ2-tests.
Table 3. The association between genotypes of RAPGEF4 SNP
rs17746510 and neuropsychiatric symptoms (presented by NPI score)
in AD patients
NPI score domain NPI scorea
TT/TG GG P-value
Behavior 0.316 0.889 0.219
Psychosis 0.065 0 0.568
Mood 1.88 4.778 *0.03
Apathy 1.213 3 *0.049
Sleep 0.382 0.889 0.279
Abbreviations: AD, Alzheimer’s disease; NPI, Neuropsychiatric Inventory;
SNP, single-nucleotide polymorphism. *Po0.05 by student’s t-test. aNPI
score is calculated by frequency of symptom occurrence and severity.
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Activation of Epac induced apoptosis in cultured primary mouse
cortical neurons via upregulation of pro-apoptotic Bcl-2 interact-
ing member protein (Bim),72 suggesting that Epac2 deﬁciency
might lead to a decrease in the newborn neuron-programmed cell
death, which resulted in impaired progenitor cell proliferation
with the similar levels of cell survival. Second, there may be a
compensatory response, during the development of Epac2− /−
mice, that results in less cell death or less competition for trophic
support to maintain the appropriate number of new neurons
compared with WT mice. Nevertheless, these speculations do not
weaken our ﬁnding that deﬁcits in cell proliferation and
early-stage hippocampal neurogenesis are associated with the
depressive-like behavior and fear-related cognitive deﬁcit of
Epac2− /− mice. The newborn neurons within 1–3 weeks after
their birth were shown to have a unique role in hippocampal-
dependent memory formation.73 These cells have high excitablility
and reduced GABAergic inhibition;74–76 therefore, they would be
preferentially activated by speciﬁc activity patterns entering the
DG. The detailed morphological characterization of DCX+ cell in
WT and Epac2− /− DG indicated that the Epac2 deﬁciency might
mainly affect the newborn cells within this period,77 which are
associated with the behavioral phenotypes in Epac2− /− mice.
In addition, adult neurogenesis is tightly regulated through the
interaction between neural stem/progenitor cells and their niche,
in which neurotransmitters are crucial environmental signals. Here
we measured the most common neurotransmitters associated
with mood disorders in the hippocampus of WT and Epac2− /−
mice. Although it is widely accepted that abnormality in the
serotonergic system is involved in the onset and the course of
depression, as well as impaired hippocampal neurogenesis,78 we
observed the normal level of 5-HT and the 5-HT turnover rate in
the hippocampus of Epac2− /− mice. Interestingly, GABA concen-
trations were signiﬁcantly reduced in the homogenate of
Epac2− /− hippocampus. Patients with major depressive disorders
have reductions of GABA in the occipital79 and the prefrontal
cortex,80 assessed using proton magnetic resonance spectroscopy.
Although there is a lack of GABA measurement in the
hippocampus of depressed individuals, preclinical studies showed
that chronic stress reduced the number and rhythmic ﬁring of
parvalbumin-positive interneurons in the hippocampus,81 indicat-
ing that function of GABAergic neurons is tightly associated with
stress-related hippocampal activity. In rodent studies, chronic
stress functionally impaired the hippocampal GABAergic neuro-
transmission, which was partially reversed by SSRI escitalopram.82
Surprisingly, SSRI ﬂuoxetine treatment did not correct the reduced
GABA level in Epac2− /− mice, although it was able to reduce the
anxiety-like behavior and improve the deﬁcit in hippocampal cell
proliferation in these mice. On the basis of this observation, we
speculated that the antidepressive and pro-neurogenic effects of
ﬂuoxetine treatment in Epac2− /− mice are, at least partially, acting
through the serotonin system. On the other hand, it is recently
discovered that GABAB receptor deletion or inhibition increased
cell proliferation in the DG.83 Epac activation reversed the GABAB
activation-induced vesicle recruitment suppression in the pre-
synaptic terminal of glutamatergic neurons.84 Therefore, Epac,
especially Epac2, has a potential role in balancing against the
GABAB receptor inhibition in transition of neural stem/progenitor
cells from quiescent to proliferative status. It remains unclear
whether the reduction of hippocampal GABA levels is the causal
factor of depression and neurogenic deﬁcits of Epac2− /− mice, or
only a compensatory effect to rescue the imbalance of GABAergic
downstream signaling.
Polymorphisms in the RAPGEF4 gene were associated with
cognitive decline and mood disturbance in patients
AD patients are observed to exhibit comorbid neuropsychiatric
symptoms, such as apathy, aggressivity, depression, anxiety,
irritability, dysphoria, aberrant motor behaviors, delusions, hallu-
cinations, disinhibition, sleep-pattern abnormalities and appetite
disturbance.85 On the other hand, stress steroids impair cognitive
function, and a history of depression increases the risk of later
development of AD.86,87 The high comorbidity implies that
progression of cognitive impairment and mood disturbance in
AD share common cellular and molecular cascades, for example,
neurogenesis.88
We initially demonstrated the signiﬁcant association of three
intronic RAPGEF4 SNPs near the catalytic domain coding sequences
with the risk of AD in Chinese patients, suggesting its role in the
pathogenesis of AD and development of dementia. Reduced Epac2
mRNA was shown in the frontal cortex and hippocampus regions
of Alzheimer's brains.89 Considering the crucial role of Epac2 in
synapse remodeling and dendrite morphology,90 decreases in
Epac2 expression in the post-mortem brain of AD patients may
result from loss of neurons and synapses in the late stage of AD.
Besides, it is speculated that Epac proteins may also involve in the
AD progression because Epac mediates secretion of the non-
amyloidogenic protective form of APP, sAPPα, induced by 5-HT4
receptor activation in vitro.91,92
Furthermore, we found a signiﬁcant association between
several SNPs in RAPGEF4 and NPI scores for apathy and mood
disturbance in AD patients. Subjects with the GG genotype of
RAPGEF4 SNP rs17746510 were more susceptible to the presenta-
tion of disturbance in mood and apathy, but not sleep disturbance
or other psychotic symptoms. Proteins of Epac2 but not Epac1
were increased in the prefrontal cortex and the hippocampus of
depressed suicide victims, together with the attenuated activation
and expression of Rap1.15 This is in line with our observation in the
mouse model that Epac2 has a predominant role in emotion
controlling. Owing to the limitation of sample availability, we did
not show functional attributes of these SNPs in the human central
nervous system. However, in silico analyses by the use of
Regulome database suggested that RAPGEF4 SNP rs17746510 falls
in highly conserved consensus-binding sequences (TGACAG) of
transcription factors such as MEIS1 (myeloid ecotropic viral
integration site 1).93 Interaction between MEIS1 and Evolutionary
Conserved Regions 1 enhancer regulates the tissue-speciﬁc
expression of neuropeptides such as substance P in the central
amygdala,94 which has a role in the modulation of fear and
anxiety. We speculated that the RAPGEF4 SNP rs17746510 might
greatly inﬂuence the expression pattern of Epac2 in the central
nervous system.
Taken together, we provided evidence that mutations of the
RAPGEF4 gene have cross-species conservative function on
cognitive and emotional regulation. In conclusion, we showed
that (1) Epac2 had a dominant role in emotional cognitive function
and mood control over Epac1; (2) impaired hippocampal
neurogenesis was among the most important factors that related
to anxiety, depressive-like behaviors and fear-related cognitive
deﬁcits in Epac2-deﬁcient mice; (3) the neurogenesis deﬁcit might
be attributed to the indispensable role of Epac2 downstream to
GABAergic regulation of recruiting quiescent cells to the active
proliferative cell pool. Investigation of the mechanistic role of
Epac2 in the cause and consequence nature of the neurogenesis–
synaptic function is being carried out. Whether there is a primary
and secondary cause underlying the mood disturbance and
memory deﬁcits in the absence of Epac2 remains a challenge for
future research. As abnormal adult neurogenesis is characterized
in a number of cognition- and emotion-related psychiatric
disorders, understanding the function of Epac sheds light on
novel treatments for neurodevelopmental and neuropsychiatric
diseases.
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